Inex Pharmaceuticals Completes Bought Deal of Common Shares ($43 million)

On December 13, 2001, Inex Pharmaceuticals Corporation completed its $43 million dollar bought deal of common shares through an underwriting syndicate led by BMO Nesbitt Burns Inc. and including Raymond James Inc., RBC Dominion Securities Inc. Yorkton Securities Inc. and Dlouhy Merchant Group Inc. Inex is a biopharmaceutical company that utilizes novel therapeutic compounds and proprietary drug delivery systems to commercialize improved therapies for the treatment of cancer. Inex's lead product, Onco TCS, is being developed with Elan Corporation, plc, and a second product, Topotecan TCS, is being developed under a partnership with GlaxoSmithKline.

Lang Michener's Vancouver office acted for Inex, with a team that included Leo Raffin, Charlotte Olsen and Barbara Snyder. The Lang Michener team was assisted by Richard Bowry of Appelby, Spurling & Kempe on matters of Bermuda law, Traci Juman of Garth St. E.W. Patterson on matters of Barbados law, Chris Barry and Randy Price of Dorsey and Whiney LLP (Seattle) on matters of U.S. law and Eugenia Garret-Wackowski of Townsend and Townsend and Crew LLP (San Francisco) on patent matters. Campney & Murphy (Vancouver) acted for the underwriters, with a team that included Iain Mant, Joseph Garcia and Bruce Tattrie.